Literature DB >> 6831170

Calcium excretion (CaE) in metastatic breast cancer.

F C Campbell, R W Blamey, A M Woolfson, C W Elston, D J Hosking.   

Abstract

In 51 women with metastatic breast cancer calcium excretion per litre of glomerular filtrate (CaE) values were persistently higher in those with bone secondaries than in those with only soft tissue involvement despite a normal range of serum calcium in both groups. Measurement of CaE in 8 further patients who were severely hypercalcaemic as a result of their advanced breast cancer revealed the degree to which calcium resorption from bone secondaries and renal dysfunction contributed to the hypercalcaemia. Thus, in patients with breast cancer, CaE provides a reliable indicator of early changes of calcium homeostasis. It may provide an objective indication of progression of bone secondaries and also has important therapeutic implications in established hypercalcaemia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831170     DOI: 10.1002/bjs.1800700405

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

1.  An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data.

Authors:  M R Williams; A Turkes; D Pearson; K Griffiths; R W Blamey
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

2.  Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.

Authors:  S H Ralston; I Fogelman; M D Gardiner; I T Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-12

3.  Mechanism of malignant hypercalcaemia in carcinoma of the breast.

Authors:  R C Percival; A J Yates; R E Gray; J Galloway; K Rogers; F E Neal; J A Kanis
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-21

4.  Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.

Authors:  R E Coleman; S Houston; I James; A Rodger; R D Rubens; R C Leonard; J Ford
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

5.  Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.

Authors:  A Berruti; A Piovesan; M Torta; C A Raucci; G Gorzegno; P Paccotti; L Dogliotti; A Angeli
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

6.  Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.

Authors:  J Vinholes; R Coleman; D Lacombe; C Rose; M Tubiana-Hulin; P Bastit; J Wildiers; J Michel; R Leonard; J Nortier; F Mignolet; J Ford
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Biochemical prediction of response of bone metastases to treatment.

Authors:  R E Coleman; K B Whitaker; D W Moss; G Mashiter; I Fogelman; R D Rubens
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

8.  Metabolic effects of pamidronate in patients with metastatic bone disease.

Authors:  J Vinholes; C Y Guo; O P Purohit; R Eastell; R E Coleman
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

Review 9.  Use of urinary markers in cancer setting: A literature review.

Authors:  Leonard Chiu; Erin Wong; Carlo DeAngelis; Nicholas Chiu; Henry Lam; Rachel McDonald; Natalie Pulenzas; Julia Hamer; Nicholas Lao; Edward Chow
Journal:  J Bone Oncol       Date:  2015-02-27       Impact factor: 4.072

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.